MHC-associated Peptide Proteomics (MAPPS) Assay Service

Serving as a powerful in vitro tool, the MHC-associated Peptide Proteomics (MAPPs) assay provides significant value for immunogenicity risk assessment of biotherapeutics through the direct identification of naturally presented T cell epitopes. Creative Biolabs' MHC-associated Peptide Proteomics (MAPPS) Assay Service is supported by a robust, automated platform that guarantees data reproducibility and systematicity. We deliver a thorough evaluation of potential T cell epitopes in candidate molecules, pinpoint immunogenic hotspots, and provide key evidence to guide early drug development, thereby furnishing a crucial foundation for de-risking candidates.

Introduction

MAPPs is a mass spectrometry-driven immune-peptidomics platform that directly captures and deciphers the repertoire of peptides naturally processed and presented on HLA class II molecules by professional antigen-presenting cells. The workflow pulses candidate biotherapeutics onto human dendritic cells, immunoaffinity-enriches the resulting HLA-peptide complexes, and subjects them to high-resolution LC-MS/MS, thereby closing an experimental loop from living cell to actionable peptide sequence.

Fig.1 MAPPs assay: a workflow for predicting ADA responses to biologics.¹

MHC-associated Peptide Proteomics (MAPPS) Assay Service at Creative Biolabs

Creative Biolabs' MHC-associated Peptide Proteomics (MAPPS) Assay Service delivers a critical profile of a biologic's immunogenic potential through direct profiling of MHC Class II-associated peptides. Our dataset allows for the accurate mapping of T cell epitopes, informing strategic decisions early in development to minimize immunogenicity risks and guide the rational design of optimized biotherapeutics.

What we can offer

Our MAPPS assay is a cornerstone service within our immunogenicity assessment portfolio, delivering the data-driven precision essential for modern drug development. We provide tailored solutions to address the unique challenges of your project, whether you are investigating novel antibodies, vaccine candidates, or complex therapeutic proteins.

Our Service Process

Required Starting Materials:

• A full-length therapeutic protein.
• Information on the sequence of protein.
• Relevant background data.

Key Steps Involved:

Final Deliverables: We deliver a final package that provides you with the full mass spectrometry dataset, including a curated list of identified peptides and their sequences, ready for downstream analysis.

Key Advantages

• Expert Team: Our service is driven by a dedicated team of Ph.D.-level scientists and highly skilled technicians, ensuring that every project benefits from deep analytical expertise and precise experimental execution.
• Proven Experience: We bring extensive experience from successfully supporting numerous client projects, which enables us to anticipate challenges, optimize study design, and deliver actionable insights tailored to your specific drug modality.
• Commitment to Quality: We are committed to superior quality through rigorous, standardized workflows and comprehensive quality controls, guaranteeing reproducible and reliable data that you can trust for critical decision-making.

FAQ

Why Choose Us?

Our MAPPS assay offers a distinct advantage over traditional in silico prediction methods by delivering experimentally validated evidence of which peptides are actually presented by human cells. Our approach significantly reduces the risk of overpredicting immunogenicity and yields a more accurate immunogenicity profile.

Customer Reviews

"By employing Creative Biolabs' MAPPS Assay Service, we gained critical insights into naturally processed and presented peptides, which substantially de-risked our lead candidate selection. The dataset not only validated our predictions but also uncovered unexpected epitopes, greatly enriching our antigen understanding." J**n S.

"The comprehensive MHC-associated peptide profiling provided by the MAPPS assay enabled us to move forward into clinical development with greater confidence. The direct correlation between protein sequence and actual MHC presentation proved decisive, streamlining our candidate selection process and conserving significant time and resources." M**a K.

"We validated Creative Biolabs' MAPPS results against internal T-cell proliferation assays and observed strong concordance, confirming its reliability as a predictive immunogenicity tool. This service offers a distinct advantage over conventional methods for early-stage immunogenicity profiling." L**y W.

How to contact us?

At Creative Biolabs, we are dedicated to supporting your research with cutting-edge, reliable services designed to accelerate your project's success. Our specialists are available to provide a detailed consultation on how our MAPPS assay service can be customized to address your unique requirements.

Reach out to our specialists today to explore potential applications for your project.

Reference

1. Lee, M Violet et al. "Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development." Frontiers in immunology vol. 14 1295285. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1295285.